Regeneron and Telix Announce Strategic Radiopharma Collaboration

Regeneron and Telix to co-develop and co-commercialize next-generation radiopharmaceutical therapies in a 50/50 cost and profit-sharing model  Collaboration combines Regeneron’s leading antibody discovery/development platforms and oncology experience with Telix’s expertise in radiopharmaceutical